Does the media prefer RYTM or TYRA?

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Rhythm Pharmaceuticals and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer MIRM or TYRA?

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Mirum Pharmaceuticals' score of 0.94 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is LNTH or TYRA more profitable?

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Tyra Biosciences N/A -42.66% -39.79%

Does the media favor LNTH or TYRA?

In the previous week, Lantheus had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Lantheus' score of 0.84 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PTCT or TYRA?

In the previous week, PTC Therapeutics had 17 more articles in the media than Tyra Biosciences. MarketBeat recorded 19 mentions for PTC Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat PTC Therapeutics' score of 0.47 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, TYRA or SRRK?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is TYRA or SRRK more profitable?

Tyra Biosciences' return on equity of -42.66% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Scholar Rock N/A -163.52% -96.67%

Does the media refer more to TYRA or SRRK?

In the previous week, Scholar Rock had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Scholar Rock and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Scholar Rock's score of 1.14 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Scholar Rock 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tyra Biosciences (TYRA) Competitors

$32.88 +0.21 (+0.64%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$32.90 +0.02 (+0.05%)

As of 05:03 AM Eastern

Compare

TYRA vs. RYTM, MIRM, LNTH, PTCT, and SRRK

Should you buy Tyra Biosciences stock or one of its competitors? MarketBeat compares Tyra Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tyra Biosciences include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), PTC Therapeutics (PTCT), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Tyra Biosciences has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.71	-$196.54M	-$3.13	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Tyra Biosciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Tyra Biosciences' return on equity of -42.66% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Tyra Biosciences	N/A	-42.66%	-39.79%

84.1% of Tyra Biosciences shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rhythm Pharmaceuticals presently has a consensus price target of $138.29, suggesting a potential upside of 25.76%. Tyra Biosciences has a consensus price target of $47.00, suggesting a potential upside of 42.94%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Rhythm Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Rhythm Pharmaceuticals and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Rhythm Pharmaceuticals' score of 1.14 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Tyra Biosciences beats Rhythm Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

84.1% of Tyra Biosciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tyra Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Tyra Biosciences	N/A	-42.66%	-39.79%

Mirum Pharmaceuticals currently has a consensus target price of $143.40, suggesting a potential upside of 18.62%. Tyra Biosciences has a consensus target price of $47.00, suggesting a potential upside of 42.94%. Given Tyra Biosciences' higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Mirum Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	14.14	-$23.36M	-$13.61	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Mirum Pharmaceuticals' score of 0.94 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Mirum Pharmaceuticals beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Lantheus had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Lantheus and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Lantheus' score of 0.84 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lantheus has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.31	$233.56M	$4.15	24.67
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Tyra Biosciences	N/A	-42.66%	-39.79%

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus presently has a consensus price target of $108.29, suggesting a potential upside of 5.78%. Tyra Biosciences has a consensus price target of $47.00, suggesting a potential upside of 42.94%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Lantheus beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, PTC Therapeutics had 17 more articles in the media than Tyra Biosciences. MarketBeat recorded 19 mentions for PTC Therapeutics and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat PTC Therapeutics' score of 0.47 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PTC Therapeutics has higher revenue and earnings than Tyra Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.74	$682.64M	-$2.33	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Tyra Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. Tyra Biosciences' return on equity of -42.66% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Tyra Biosciences	N/A	-42.66%	-39.79%

PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PTC Therapeutics currently has a consensus target price of $91.57, indicating a potential upside of 17.31%. Tyra Biosciences has a consensus target price of $47.00, indicating a potential upside of 42.94%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Tyra Biosciences beats PTC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Scholar Rock?

Tyra Biosciences (NASDAQ:TYRA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Tyra Biosciences' return on equity of -42.66% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Scholar Rock	N/A	-163.52%	-96.67%

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tyra Biosciences has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

In the previous week, Scholar Rock had 1 more articles in the media than Tyra Biosciences. MarketBeat recorded 3 mentions for Scholar Rock and 2 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.61 beat Scholar Rock's score of 1.14 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Scholar Rock	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences currently has a consensus price target of $47.00, suggesting a potential upside of 42.94%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 4.13%. Given Tyra Biosciences' higher possible upside, equities analysts clearly believe Tyra Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Summary

Tyra Biosciences beats Scholar Rock on 8 of the 13 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-15.08	20.98	27.01	24.38
Price / Sales	N/A	311.10	521.33	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	6.77	8.54	10.95	6.33
Net Income	-$119.95M	$23.83M	$3.59B	$331.02M
7 Day Performance	0.95%	-2.77%	-1.45%	-0.33%
1 Month Performance	15.17%	5.85%	2.78%	-1.29%
1 Year Performance	224.58%	52.15%	28.53%	21.30%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	2.6532 of 5 stars	$32.88 +0.6%	$47.00 +42.9%	+201.4%	$1.94B	N/A	N/A	20	Positive News
RYTM Rhythm Pharmaceuticals	3.0364 of 5 stars	$109.96 +2.3%	$138.29 +25.8%	+23.3%	$7.37B	$189.76M	N/A	140	Positive News Gap Down
MIRM Mirum Pharmaceuticals	2.6221 of 5 stars	$120.89 +1.6%	$143.40 +18.6%	+126.9%	$7.26B	$521.31M	N/A	140	Gap Down
LNTH Lantheus	3.0348 of 5 stars	$102.37 -2.9%	$108.29 +5.8%	+23.2%	$6.86B	$1.54B	24.67	1,193
PTCT PTC Therapeutics	3.3362 of 5 stars	$78.06 -4.0%	$91.57 +17.3%	+57.8%	$6.75B	$1.73B	N/A	1,410	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. RYTM, MIRM, LNTH, PTCT, and SRRK

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Lantheus?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Summary

How does Tyra Biosciences compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. RYTM, MIRM, LNTH, PTCT, and SRRK

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Which has higher valuation and earnings, RYTM or TYRA?

Is RYTM or TYRA more profitable?

Do institutionals & insiders have more ownership in RYTM or TYRA?

Do analysts rate RYTM or TYRA?

Which has more risk and volatility, RYTM or TYRA?

Does the media prefer RYTM or TYRA?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Do institutionals and insiders have more ownership in MIRM or TYRA?

Is MIRM or TYRA more profitable?

Do analysts rate MIRM or TYRA?

Which has stronger earnings & valuation, MIRM or TYRA?

Which has more risk & volatility, MIRM or TYRA?

Does the media prefer MIRM or TYRA?

Summary

How does Tyra Biosciences compare to Lantheus?

Does the media favor LNTH or TYRA?

Which has better valuation & earnings, LNTH or TYRA?

Is LNTH or TYRA more profitable?

Which has more volatility & risk, LNTH or TYRA?

Do insiders and institutionals have more ownership in LNTH or TYRA?

Do analysts rate LNTH or TYRA?

Summary

How does Tyra Biosciences compare to PTC Therapeutics?

Does the media prefer PTCT or TYRA?

Which has better earnings & valuation, PTCT or TYRA?

Is PTCT or TYRA more profitable?

Which has more volatility & risk, PTCT or TYRA?

Do insiders & institutionals have more ownership in PTCT or TYRA?

Do analysts prefer PTCT or TYRA?

Summary

How does Tyra Biosciences compare to Scholar Rock?

Which has stronger earnings and valuation, TYRA or SRRK?

Is TYRA or SRRK more profitable?

Do institutionals and insiders hold more shares of TYRA or SRRK?

Which has more risk and volatility, TYRA or SRRK?

Does the media refer more to TYRA or SRRK?

Do analysts prefer TYRA or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools